Table 3.

Correlations of the pretreatment, 2-week change, 2-week posttreatment, and 16-week posttreatment levels of the breast cancer hypoxia metagene

Pretreatment Ki67 (log2)Pretreatment proliferation metagene2-wk Ki67 (log2)2-wk percentage change in Ki67
A. Pretreatment hypoxia metagene r = 0.55, P < 10−4 r = 0.67, P < 10−4 r = 0.43, P = 0.0002 rs = 0.22, P = 0.07
2-wk percentage change in Ki67 2-wk change in proliferation metagene 2-wk change in AvERG 2-wk change in TFF1/pS2
B. 2-wk change in hypoxia metagene rs = 0.33, P = 0.007 r = 0.69, P < 10−4 r = 0.05, P = 0.7 r = 0.007, P = 0.9
2-wk Ki67 (log2) 2-wk posttreatment proliferation metagene
C. 2-wk posttreatment hypoxia metagene r = 0.58, P < 10−4 r = 0.71, P < 10−4
16-wk Ki67 (log2) 16-wk posttreatment proliferation metagene
D. 16-wk posttreatment hypoxia metagene r = 0.50, P = 0.03 r = 0.73, P = 0.0003